Related Experiment Videos
Complement activation and bioincompatibility. The terminal complement complex for evaluation and surface modification
T E Mollnes1, V Videm, J Riesenfeld
1Institute of Immunology and Rheumatology, Rikshospitalet, University of Oslo, Norway.
Clinical and Experimental Immunology
|October 1, 1991
Summary
Evaluating biomaterial biocompatibility using terminal complement complex activation is effective. Modifying artificial surfaces with heparin improves biocompatibility, reducing adverse effects in medical devices.
Area of Science:
- Biomaterials Science
- Immunology
- Medical Device Engineering
Background:
- Biocompatibility assessment is crucial for medical devices.
- Complement activation is a key indicator of adverse material reactions.
- Existing assays for biocompatibility have limitations.
Purpose of the Study:
- To evaluate the terminal complement complex as a biomarker for biomaterial biocompatibility.
- To assess the impact of heparin surface modification on biomaterial biocompatibility.
Main Methods:
- Assessing terminal complement complex formation on biomaterials.
- Utilizing cardiopulmonary bypass devices as a model system.
- Comparing unmodified and heparin-modified artificial surfaces.
Main Results:
- Terminal complement complex activation accurately indicates biomaterial biocompatibility.
- Heparin surface modification significantly improved the biocompatibility of artificial surfaces.
- Reduced adverse effects were observed with heparin-modified materials.
Conclusions:
- The terminal complement complex is a reliable indicator for evaluating biomaterial biocompatibility.
- Functional heparin surface modification enhances the biocompatibility of medical devices.
- This approach offers improved safety for patients using such devices.